Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus
Authors
Keywords
-
Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 14, Issue 16, Pages 2281-2296
Publisher
Informa Healthcare
Online
2013-10-03
DOI
10.1517/14656566.2013.838559
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and Safety of Lixisenatide Once-Daily Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled on Metformin (GetGoal-M)
- (2013) Bo Ahrén et al. DIABETES CARE
- Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin
- (2013) Matthew C. Riddle et al. DIABETES CARE
- Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine
- (2013) Matthew C. Riddle et al. DIABETES CARE
- Effect of vildagliptin compared to glimepiride on postprandial proinsulin processing in the β cell of patients with type 2 diabetes mellitus
- (2013) T. Forst et al. DIABETES OBESITY & METABOLISM
- Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin
- (2013) C. Kapitza et al. DIABETES OBESITY & METABOLISM
- Effects of lixisenatide once daily on gastric emptying in type 2 diabetes — Relationship to postprandial glycemia
- (2013) Martin Lorenz et al. REGULATORY PEPTIDES
- Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy: A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)
- (2012) V. A. Fonseca et al. DIABETES CARE
- Reducing cardiovascular disease risk in type 2 diabetes: is the focus on glycaemia warranted?
- (2012) L. D. Ferguson et al. DIABETES OBESITY & METABOLISM
- Weight changes and their predictors amongst 11 140 patients with type 2 diabetes in the ADVANCE trial
- (2012) S. van Dieren et al. DIABETES OBESITY & METABOLISM
- Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)
- (2012) Y. Seino et al. DIABETES OBESITY & METABOLISM
- Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function
- (2012) T. Forst et al. DIABETIC MEDICINE
- Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2012) S. E. Inzucchi et al. DIABETOLOGIA
- Cardiovascular Biology of the Incretin System
- (2012) John R. Ussher et al. ENDOCRINE REVIEWS
- GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
- (2012) Juris J. Meier Nature Reviews Endocrinology
- Rapid Tachyphylaxis of the Glucagon-Like Peptide 1-Induced Deceleration of Gastric Emptying in Humans
- (2011) M. A. Nauck et al. DIABETES
- Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology
- (2011) D. J. Drucker et al. DIABETOLOGIA
- Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes
- (2011) R. Kodera et al. DIABETOLOGIA
- Epidemiology and Economic Impact of Obesity and Type 2 Diabetes
- (2011) Hazem Shamseddeen et al. SURGICAL CLINICS OF NORTH AMERICA
- Incretin-Based Therapies for Type 2 Diabetes Mellitus: Properties, Functions, and Clinical Implications
- (2010) Michael A. Nauck AMERICAN JOURNAL OF MEDICINE
- Possible involvement of GLP-1(9-36) in the regional haemodynamic effects of GLP-1(7-36) in conscious rats
- (2010) SM Gardiner et al. BRITISH JOURNAL OF PHARMACOLOGY
- Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial
- (2010) S. Del Prato et al. DIABETES OBESITY & METABOLISM
- RETRACTED ARTICLE: A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells
- (2010) Y. Hattori et al. DIABETOLOGIA
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
- (2010) Richard M Bergenstal et al. LANCET
- Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes
- (2010) Ulrich Werner et al. REGULATORY PEPTIDES
- Little enhancement of meal-induced glucagon-like peptide 1 secretion in Japanese: Comparison of type 2 diabetes patients and healthy controls
- (2010) Daisuke Yabe et al. Journal of Diabetes Investigation
- Effects of Exenatide on Systolic Blood Pressure in Subjects With Type 2 Diabetes
- (2009) T. Okerson et al. AMERICAN JOURNAL OF HYPERTENSION
- The role of incretins in cardiovascular control
- (2009) Derek D. Mafong et al. CURRENT HYPERTENSION REPORTS
- Incretin-Based Therapies: Viewpoints on the way to consensus
- (2009) Michael. A. Nauck et al. DIABETES CARE
- Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
- (2009) M. Marre et al. DIABETIC MEDICINE
- Exenatide once weekly for the treatment of type 2 diabetes
- (2009) James Malone et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
- (2009) John B Buse et al. LANCET
- Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis
- (2009) Eva Tomas et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways
- (2008) Kiwon Ban et al. CIRCULATION
- Robust improvements in fasting and prandial measures of β-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database
- (2008) R. E. Pratley et al. DIABETES OBESITY & METABOLISM
- Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes
- (2008) J.-P. Courrèges et al. DIABETIC MEDICINE
- Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus
- (2008) T. Vilsbøll et al. DIABETIC MEDICINE
- Insulin sensitivity measured by the euglycaemic insulin clamp and proinsulin levels as predictors of stroke in elderly men
- (2008) B. Wiberg et al. DIABETOLOGIA
- Enhanced Protection against Cytokine- and Fatty Acid-induced Apoptosis in Pancreatic Beta Cells by Combined Treatment with Glucagon-like Peptide-1 Receptor Agonists and Insulin Analogues
- (2008) D. Tews et al. HORMONE AND METABOLIC RESEARCH
- Guideline for management of postmeal glucose
- (2008) Antonio Ceriello et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now